{
    "nct_id": "NCT03890731",
    "official_title": "A Single Arm, Open-label, Multicenter Phase 2 Study of Regorafenib in Participants Who Have Been Treated in a Previous Bayer-sponsored Regorafenib Study (Monotherapy or Combination Treatment) That Has Reached the Primary Completion Endpoint or the Main Data Analysis, or Has Been Stopped Prematurely.",
    "inclusion_criteria": "* Participant must be age-eligible in the feeder study at the time of signing the informed consent.\n* Participant is currently participating in any Bayer-sponsored regorafenib study and is receiving study treatment.\n* Participant is currently benefiting from treatment with regorafenib monotherapy and meets criteria to initiate a subsequent cycle of therapy, as determined by the guidelines of the feeder protocol.\n* Any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption by the investigator.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Medical reasons not to start the next treatment cycle in the respective feeder\n* Pregnancy",
    "miscellaneous_criteria": ""
}